65.17 亿元，同比增速分别为 9.5%、20.3%、19.8%，实现归母净利润 为 4.09、5.33、6.87 亿元，同比分别增长 106.0%、30.4%、28.9%， 对应当前股价 PE 分别为 13、10、8 倍。 | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------|---------------|---------------|---------------|---------------|-------------| | [Table_Profit] 重要财务指标 营业总收入 ( 百万元 ) | 2022A 6,138 | 2023A 4,127 | 2024E 4,519 | 2025E 5,439 | 2026E 6,517 | | 增长率 YoY % | 20.5% | -32.8% | 9.5% | 20.3% | 19.8% | | 归属母公司净利润 | 680 | 198 | 409 | 533 | 687 | | 百万元 ) 增长率 YoY% ...

中信证券股份有限公司 关于振德医疗用品股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为振德 医疗用品股份有限公司（以下简称"振德医疗"或"公司"）2021 年度非公开发 行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号—持续督导》《上 海证券交易所上市公司自律监管指引第 1 号—规范运作》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》等有关规定，对公司 2023 年 度募集资金存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 1、公开发行可转换债券实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2019〕2008 号文核准，公司发行可 转换公司债券 4,400,000 张，每张面值为人民币 100.00 元，按面值发行，共计募 集资金人民币 44,000.00 万元，扣除发行费用后本次募集资金净额为人民币 42,969.06 万元，已由主承销商中信证券于 ...

2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2024 年 4 月 29 日（星期一） 至 5 月 8 日（星 期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明 会上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2024 年 4 月 27 日发布公司 2023 年度报告以及 2024 年第一季度报告。为便于 广大投资者更全面深入地了解公司2023 年度及2024 年第一季度的经 营成果、财务状况，公司计划于 2024 年 5 月 9 日上午 10:00-11:00 举行 2023 年度暨 2024 年第一季度业绩说明会，就投资者关心的问题 进行交流。 振德医疗用品股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥963,887,437.65, representing a decrease of 25.88% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥73,397,631.01, down 49.89% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.28, reflecting a decrease of 49.09% compared to the same period last year[5]. - Total operating revenue for Q1 2024 was ¥963,887,437.65, a decrease of 25.9% compared to ¥1,300,476,798.62 in Q1 2023[17]. - Net profit for Q1 2024 was ¥75,230,110.17, a decline of 49.1% from ¥147,985,140.95 in Q1 2023[18]. - Earnings per share for Q1 2024 were ¥0.28, compared to ¥0.55 in Q1 2023[19]. Profitability and Margins - The gross profit margin for the main business was 34.90%, with a 6.19 percentage point increase year-on-year when excluding isolation protective products[8]. - The weighted average return on equity decreased by 1.25 percentage points to 1.36%[5]. - The company reported a significant decline in revenue from isolation protective products, which amounted to ¥51,153,300, a decrease of 87.66% year-on-year[8]. Cash Flow and Operating Activities - Cash flow from operating activities increased by ¥231,668,400 compared to the previous year, mainly due to reduced payments for employee wages and taxes[8]. - In Q1 2024, the cash inflow from operating activities was CNY 1,048,332,483.77, a decrease of 25% compared to CNY 1,397,604,503.80 in Q1 2023[20]. - The net cash flow from operating activities turned positive at CNY 26,297,173.49, compared to a negative CNY 205,371,184.05 in the same period last year[22]. - Cash outflow for operating activities decreased to CNY 1,022,035,310.28, down 36% from CNY 1,602,975,687.85 in Q1 2023[22]. Assets and Liabilities - Total assets at the end of Q1 2024 were ¥8,005,323,343.11, an increase of 10.16% from the end of the previous year[6]. - The company's total liabilities increased to ¥2,297,225,449.44 in Q1 2024 from ¥1,662,319,359.19 in Q1 2023, representing a growth of 38.2%[16]. - Non-current liabilities rose to ¥959,902,362.67 in Q1 2024, up from ¥490,023,761.75 in Q1 2023, marking an increase of 96.0%[16]. - The company's total equity increased to ¥5,708,097,893.67 in Q1 2024 from ¥5,604,400,315.51 in Q1 2023, reflecting a growth of 1.8%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,896[10]. - The company reported a pledge of 23,547,880 shares by its largest shareholder, Zhejiang Zhend Medical Holdings Co., Ltd., which holds 49.82% of the shares[12]. - The company has no significant changes in the participation of major shareholders in margin financing and securities lending activities[12]. Research and Development - Research and development expenses decreased to ¥29,493,825.79 in Q1 2024 from ¥42,093,960.50 in Q1 2023, a reduction of 30.0%[17]. Other Income and Expenses - Other income for Q1 2024 was ¥11,704,234.34, significantly higher than ¥4,083,356.56 in Q1 2023, indicating an increase of 187.5%[18]. - The company recorded non-operating income and expenses totaling -¥1,298,414.20, after accounting for tax and minority interests[8]. - The company reported a fair value change loss of ¥1,841,014.94 in Q1 2024, compared to a gain of ¥14,606,416.45 in Q1 2023[18]. Inventory and Current Assets - The company's inventory decreased to CNY 770,411,652.87 from CNY 800,806,476.52, showing a decline of about 3.8%[14]. - Total current assets increased to CNY 3,290,568,290.28 from CNY 2,719,806,144.11, reflecting a growth of approximately 21%[14]. - The company's accounts receivable increased to CNY 559,536,019.08 from CNY 539,646,098.58, which is an increase of about 3.7%[13]. Financing Activities - Cash inflow from financing activities increased significantly to CNY 1,127,760,000.00, compared to CNY 534,900,000.00 in the previous year, marking a 111% increase[22]. - The net cash flow from financing activities was CNY 698,234,792.57, up from CNY 474,244,778.31 in Q1 2023[22].

振德医疗用品股份有限公司 2023 年度独立董事述职报告 作为振德医疗用品股份有限公司（以下简称"公司"）独立董事， 在 2023 年度的工作中，本人严格按照《公司法》、《证券法》、《上市 公司独立董事管理办法》及其他有关法律法规和《公司章程》、《公司 独立董事工作制度》等规定和要求，切实履行独立董事职责，积极参 加公司股东大会、董事会会议以及各专门委员会会议，利用自身的专 业知识为公司发展提出建议，促进公司规范运作，切实维护公司利益 和全体股东特别是中小股东的合法权益。现将 2023 年度履行职责情 况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 倪崖先生，出生于 1961 年 11 月，中国国籍，无境外永久居留 权，二级研究员、硕士；历任浙江省医学科学院生物工程研究所副研 究员、副院长，浙江普发科技开发中心总经理，浙江普康生物技术股 份有限公司董事，浙江省医学科学院药物研究所研究员、副院长；现 任公司独立董事，杭州医学院/浙江省医学科学院药物研究所二级研 究员，中国医药生物技术协会转化医学分会副主委、中国转化医学联 盟细胞生物学分会会长、浙江省转化医学学会副理事长、浙江省细胞 ...

目 录 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 天健审〔2024〕3688 号 振德医疗用品股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了振德医疗用品股份有限公司（以下简称振德医疗公司）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是振德 医疗公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 二〇二四年四月二十五日 第 2 页 共 2 页 四、财务报告内部控制审计意见 我们认为，振德医疗公司于 2 ...

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 募集资金年度存放与使用情况鉴证报告 天健审〔2024〕3687 号 振德医疗用品股份有限公司全体股东： 我们鉴证了后附的振德医疗用品股份有限公司（以下简称振德医疗公司）管 理层编制的 2023 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供振德医疗公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为振德医疗公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 振德医疗公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》（证监会公告〔2022〕15 号）和《上海证券交易所上市公司自律监管 指引第 1 号——规范运作（2023 年 12 月修订）》（上证发〔2023〕193 号）的 规定编制《关于募集资金年度存放与使用情况的专项报告》，并保证其内容真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 三、注册会计师的责任 我们的责任是在实 ...

Financial Performance - In 2023, the company's operating revenue was CNY 4,127,044,057.44, a decrease of 32.76% compared to CNY 6,137,634,431.69 in 2022[23]. - The net profit attributable to shareholders was CNY 198,399,010.76, down 70.82% from CNY 679,878,142.51 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 189,587,741.53, a decline of 72.99% compared to CNY 701,971,558.62 in 2022[23]. - Cash generated from operating activities was CNY 452,107,162.00, a decrease of 63.72% from CNY 1,246,045,055.93 in the previous year[23]. - As of the end of 2023, the total equity attributable to shareholders was CNY 5,365,596,147.58, a decrease of 3.16% from CNY 5,540,487,960.96 at the end of 2022[23]. - The company's basic earnings per share (EPS) decreased by 74.22% to CNY 0.74 in 2023 from CNY 2.87 in 2022[25]. - The weighted average return on equity (ROE) dropped to 3.60% in 2023, down 11.21 percentage points from 14.81% in 2022[25]. - The company achieved a main business revenue of 4.105 billion yuan in 2023, a decrease of 33.04% year-on-year, with net profit attributable to shareholders of 198 million yuan, down 70.82% year-on-year[37]. - The company reported a net profit of CNY -102 million in Q4 2023, indicating a significant loss in that quarter[30]. Revenue Breakdown - The net profit attributable to shareholders decreased significantly due to a drop in demand for isolation protective products, with sales revenue from these products falling by CNY 2.19 billion to CNY 583 million[26]. - The revenue excluding isolation protective products grew by 5.34% year-on-year, reaching CNY 3.544 billion[26]. - The company achieved domestic main business revenue of 1.947 billion yuan, a decrease of 52.56% year-on-year, with online and offline retail business revenue of 861 million yuan[40]. - The company’s overseas main business revenue reached 2.159 billion yuan, an increase of 6.49% year-on-year, with a growth of 8.32% when excluding isolation protective products[42]. - Excluding isolation protective products, the company's main business revenue was 3.522 billion yuan, representing a year-on-year growth of 4.90%[37]. Product Development and Innovation - The company is committed to innovation-driven development, collaborating with universities to enhance technical innovation capabilities and improve product performance[43]. - The company achieved significant results in the development of infection control materials, with the first surgical infection control product meeting ISCC certification requirements completing mass production and delivery[44]. - The company has established a product matrix under the "one main and two auxiliary groups" strategy, focusing on family health care and the silver-haired market[38]. - The company has initiated three domestic and international co-development projects for modern wound care products during the reporting period[41]. - The company is focused on expanding its market presence and enhancing product offerings in the healthcare sector[71]. Market Strategy and Expansion - The company expanded its hospital coverage to over 8,000 hospitals nationwide, an increase of more than 1,000 hospitals compared to the beginning of the reporting period, with approximately 1,150 being top-tier hospitals[38]. - The company is actively enhancing its supply chain capabilities and accelerating the construction of overseas production bases, with the African production base expected to be operational in early 2024[41]. - The company is exploring partnerships with healthcare providers to expand its distribution channels, targeting a 20% increase in sales through these collaborations[158]. - The company aims to implement a dual-driven strategy focusing on "medical + health," enhancing product innovation and optimizing product line layout to achieve high-quality development in 2024[133]. - The international market strategy involves leveraging product quality and new product launches to increase market share, while also establishing overseas production bases to meet diverse supply chain needs[135]. Risk Management and Compliance - The company has detailed the potential risks it may face in its future development in the report[9]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors[7]. - The company has established a robust quality management system to mitigate risks associated with product quality and ensure high standards in its medical supplies[144]. - The company faces risks from regulatory changes and market competition, necessitating continuous adaptation to industry policies and enhancement of operational management[144]. - The company has implemented strict risk control measures for foreign exchange transactions, including timely monitoring of customer payment capabilities and enhancing collection efforts[120]. Governance and Shareholder Relations - The company held three shareholder meetings during the reporting period, ensuring fair treatment of all shareholders, especially minority shareholders[149]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of independent directors being at least one-third of the total[150]. - The company strictly adheres to legal regulations for information disclosure, ensuring transparency and fairness in its communications[151]. - The company has established a robust governance structure, with specialized committees enhancing decision-making processes[150]. - The company emphasizes investor relations through various communication channels, enhancing understanding and trust among shareholders[151]. Environmental and Social Responsibility - The company invested 10.48 million yuan in environmental protection during the reporting period[193]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[194]. - The company has implemented ISO14001 and ISO45001 certifications, enhancing its environmental management and occupational health safety systems[195]. - The company emphasizes energy conservation and pollution reduction as part of its sustainable development strategy[198]. - The company has disclosed its 2022 Sustainable Development Report and ESG Report on August 30 and September 23, 2023[196].

证券代码：603301 证券简称：振德医疗 公告编号：2024-010 振德医疗用品股份有限公司 关于公司会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、本次会计政策变更是振德医疗用品股份有限公司（以下简称 "公司"）因执行财政部于 2023 年 10 月 25 日发布的《企业会计准则 解释第 17 号》(财会〔2023〕21 号，以下简称"《准则解释第 17 号》") 对公司会计政策进行相应的变更。 2、本次会计政策变更不追溯调整以前年度可比数，不影响公司 以前年度相关财务指标。 一、本次会计政策变更概述 2023 年 10 月 25 日，财政部颁布了《准则解释第 17 号》，其中 规定"关于流动负债与非流动负债的划分"、"关于供应商融资安排的 披露"、"关于售后租回交易的会计处理"的内容，要求自 2024 年 1 月 1 日起施行。 二、会计政策变更的主要内容 本次会计政策变更前，公司执行财政部颁布的《企业会计准则— —基本准则》和各项具体会计准则、后续发布和修订的企业会计准则、 企 ...

振德医疗用品股份有限公司 关于公司 2024 年度申请综合授信额度暨在授信额度 内为子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司 2024 年 4 月 25 日召开了第三届董事 会第十三次会议，审议通过了《关于公司 2024 年度申请综合授信额 度暨在授信额度内为子公司提供担保的议案》，本议案尚需提交股东 大会审议。 为满足公司生产经营活动的需要，确保顺利实现公司年度经营计 划和目标，公司及全资、控股子公司（以下简称"公司"）2024 年度 拟向金融机构申请总额不超过人民币 180,000 万元的综合授信。综合 授信品种包括但不限于：流动资金贷款、项目资金贷款、银行承兑汇 票、保函、信用证、抵（质）押贷款等各种贷款及贸易融资业务（具 体业务品种以相关金融机构审批意见为准）。实际融资金额将视公司 生产经营资金需求及金融机构实际审批的授权额度来确认。在授信期 限内，上述授信额度可循环滚动使用。 根据公司 2024 年度经营计划及全资、控股子公司的业务发展状 况，公司及全资、控股子公 ...